Novartis Ag

David Carcache

Manuel Koller

David Orain

Hans Allgeier

Yves Auberson

Dirk Behnke

Johanne Renaud

Philipp Floersheim

Peter Ertl

Oliver Simic

Joerg Kallen

Joachim Nozulak

Wolfgang Froestl

Henri Mattes

Jörg Kallen

Christel Guibourdenche

Carsten Spanka

Richard Heng

Danilo Guerini

Florian Gruber

Martin Gunzenhauser

Francesca Perruccio

The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Rthrough Rare as defined herein, and methods of making and using the same.

Compounds and compositions for treating conditions associated with cGAS

The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Diazepinone derivatives

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein Rand Rare as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy

N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide

Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands

Growing community of inventors

Binningen, Switzerland

David Carcache